Martin Sanda
Overview
Explore the profile of Martin Sanda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
739
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prokhnevska N, Cardenas M, Valanparambil R, Sobierajska E, Barwick B, Jansen C, et al.
Immunity
. 2022 Dec;
56(1):107-124.e5.
PMID: 36580918
Improvements in tumor immunotherapies depend on better understanding of the anti-tumor T cell response. By studying human tumor-draining lymph nodes (TDLNs), we found that activated CD8 T cells in TDLNs...
2.
Weng X, Zhong L, Xiang P, Li Y, Paciorek A, Dong L, et al.
Eur J Cancer Care (Engl)
. 2022 Oct;
31(6):e13740.
PMID: 36239065
Objective: We evaluate cost-effectiveness of primary treatments for localised prostate cancer by uniquely combining prospectively collected real-world outcomes and costs from UCSF Cancer of Prostate Strategic Urologic Research Endeavor (CaPSURE™)....
3.
Seymour Z, Daignault-Newton S, McLaughlin P, Sandler H, Jackson W, Johnson S, et al.
Clin Transl Radiat Oncol
. 2022 Jul;
36:56-62.
PMID: 35813938
Objective/purpose: Previously patient reported quality of life (QOL) was reported in men with prostate cancer a mean 2 and 6 years post treatment with open radical prostatectomy (RP), 3D conformal...
4.
Fischer-Valuck B, Baumann B, Brown S, Filson C, Weiss A, Mueller R, et al.
Eur Urol Open Sci
. 2022 Mar;
37:80-89.
PMID: 35243392
Background: Elderly patients diagnosed with high-risk prostate cancer (PCa) present a therapeutic dilemma of balancing treatment of a potentially lethal malignancy with overtreatment of a cancer that may not threaten...
5.
Alemozaffar M, Akintayo A, Abiodun-Ojo O, Patil D, Saeed F, Huang Y, et al.
J Urol
. 2020 Apr;
204(4):734-740.
PMID: 32347780
Purpose: Accurate preoperative staging of prostate cancer is essential for treatment planning. Conventional imaging is limited in detection of metastases. Our primary aim was to determine if [F]fluciclovine positron emission...
6.
Morgan T, Rossi P, Cutrell P, Zhang C, Press R, Rahnema S, et al.
Brachytherapy
. 2019 Jul;
18(6):793-799.
PMID: 31337543
Purpose: The purpose of the study was to report our institutional quality of life data for those undergoing high-dose-rate brachytherapy with an International Prostate Symptom Score (IPSS) ≥15 compared with...
7.
Morgan T, Press R, Cutrell P, Zhang C, Chen Z, Rahnema S, et al.
J Contemp Brachytherapy
. 2019 Jan;
10(6):495-502.
PMID: 30662471
Purpose: To report our institutional quality of life (QOL) data for low-dose-rate (LDR) monotherapy (LDR mono), high-dose-rate (HDR) monotherapy (HDR mono), and EBRT with an HDR brachytherapy boost (HDR boost)....
8.
Press R, Morgan T, Cutrell P, Zhang C, Chen Z, Rahnema S, et al.
Brachytherapy
. 2018 Sep;
18(1):13-21.
PMID: 30262410
Purpose: Patients with large prostate glands are underrepresented in clinical trials incorporating brachytherapy due to concerns for excessive toxicity. We sought to compare health-related quality of life (HRQOL) outcomes between...
9.
Morgan T, Press R, Cutrell P, Zhang C, Chen Z, Rahnema S, et al.
J Contemp Brachytherapy
. 2018 Jul;
10(3):211-217.
PMID: 30038640
Purpose: There is limited data to support the use of hypofractionated external beam radiation (HypoF) in combination with high-dose-rate brachytherapy (HDR). We report our quality of life (QOL) outcomes when...
10.
Avila M, Patel L, Lopez S, Cortes-Sanabria L, Garin O, Pont A, et al.
Cancer Treat Rev
. 2018 Apr;
66:23-44.
PMID: 29673922
Background: The aim of this systematic review is to assess the impact of primary treatments with curative intention in patients with localized prostate cancer, measured with Patient-Reported Outcomes (PROs), and...